Boehringer Ingelheim and Lilly present full results of Trajenta®’s CARMELINA® cardiovascular outcome trial
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today presented the full results of the long-term cardiovascular outcome trial, CARMELINA®, which studied the impact of Trajenta® (linagliptin) on cardiovascular and kidney safety in adults with type 2 diabetes at high risk for heart and/or kidney disease.1,2 The study met its primary endpoint,* with linagliptin demonstrating a similar cardiovascular safety profile compared to placebo when added to standard of care.1 CARMELINA® also included a key secondary composite endpoint,† showing a similar kidney safety profile compared to placebo.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181004005553/en/
The overall safety profile of linagliptin in CARMELINA® was consistent with previous data and no new safety signals were observed.1 CARMELINA® also showed a similar rate of hospitalisation for heart failure for linagliptin compared to placebo.1
The full results were presented at the 54th European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, Germany.
“Heart disease is a major complication and the leading cause of death for people living with type 2 diabetes. CARMELINA® adds important new evidence for type 2 diabetes patients at high risk of heart and/or kidney disease, a population that has been underrepresented in other cardiovascular outcome trials, but whom we see in our daily practice. The trial confirmed that linagliptin can be used with confidence in this patient population,” commented Bernard Zinman, M.D., Professor in the Department of Medicine, University of Toronto and Senior Scientist at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.
In CARMELINA®, cardiovascular events that contributed to the primary endpoint* occurred in 12.4 percent (434 people) of the linagliptin group compared to 12.1 percent (420 people) in the placebo group, demonstrating a similar long-term cardiovascular safety profile in adults with type 2 diabetes.1 Linagliptin also showed a similar long-term kidney safety profile compared to placebo. This was demonstrated on the composite endpoint reflecting declining kidney function† occurring in 9.4 percent (327 people) of the linagliptin group compared to 8.8 percent (306 people) of the placebo group.1
An increase in the risk of hospitalisation for heart failure has been observed in some other cardiovascular outcome trials in diabetes.3,4 In CARMELINA®, this endpoint was pre-specified and assessed thoroughly via adjudication.‡ Hospitalisation for heart failure occurred in 6 percent (209 people) of the linagliptin group compared to 6.5 percent (226) of the placebo group.1 “These results are particularly meaningful given the patient population in CARMELINA, including those most vulnerable to developing heart failure,” said Waheed Jamal, MD, Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim.
“While many guidelines5,6 now recognise the importance of choosing a diabetes treatment with a proven benefit on reducing cardiovascular risk and mortality in people with type 2 diabetes and heart disease, there remains a need for additional glucose-lowering options,” Waheed Jamal pointed out. “CARMELINA® reinforces confidence in linagliptin as an effective and well-tolerated treatment, with a simple dosing regimen for adults with type 2 diabetes.”
“We have created a unique cardiovascular outcome trial programme for linagliptin with two trials — CARMELINA®, whose results are released today, as well as CAROLINA®, which will report initial results in the near future,” added Jeff Emmick, MD, PhD, Vice President, Product Development, Lilly Diabetes. “This programme will provide clinical data on the long-term safety profile of linagliptin in a broad range of adults with type 2 diabetes, which reflects patients that doctors see in their daily practice.7”
CARMELINA® is a multi-national, randomised, double-blind, placebo-controlled clinical trial that involved 6,979 adults with type 2 diabetes from 27 countries at more than 600 sites observed for a median duration of 2.2 years.2,8 The study was designed to assess the effect of linagliptin (5mg once daily) compared to placebo (both added to standard of care) on cardiovascular outcomes in adults with type 2 diabetes and high cardiovascular risk, the majority of whom also had kidney disease.2,8 This population of people with high risk of cardiovascular and/or kidney disease reflects patients that doctors see in their daily practice.7 Standard of care included both glucose lowering agents and cardiovascular drugs (including antihypertensive and lipid lowering agents).
CARMELINA® was led by an academic trial steering committee and the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance. Compared to other recently reported outcome trials of dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes, CARMELINA® included the highest number of patients with impaired kidney function.§
To learn more about CARMELINA®, please visit: https://www.carmelinatrial.com/
Trajenta® is a one dose, once daily DPP-4 inhibitor that provides significant efficacy in the reduction of blood sugar levels for adults with type 2 diabetes. It can be prescribed for adult patients with type 2 diabetes regardless of age, disease duration, ethnicity, body mass index (BMI), liver and kidney function.9 Trajenta® has the lowest kidney excretion rate of all DPP-4 inhibitors.9-13
About our cardiovascular outcome trials
As cardiovascular disease is a major complication and the leading cause of death in type 2 diabetes,14 cardiovascular safety of all type 2 diabetes treatments is important. Worldwide, most people with type 2 diabetes die of a cardiovascular event.15 In 2015, Boehringer Ingelheim and Eli Lilly and Company announced results from the landmark cardiovascular outcome trial EMPA-REG OUTCOME® with the SGLT2 inhibitor empagliflozin.16,17
CARMELINA® is one of two cardiovascular outcome trials with the DPP-4 inhibitor linagliptin. CAROLINA®,18 will be the first DPP-4 inhibitor cardiovascular outcome trial to compare commonly used second line treatments — linagliptin and the sulphonylurea glimepiride. This trial includes adults with relatively early type 2 diabetes and increased cardiovascular risk or established complications, with less than optimised blood sugar control. The majority did not yet have heart and kidney disease. The study will report initial results in the near future. CARMELINA® and CAROLINA® will provide clinical data on the long-term safety profile of linagliptin in a broad range of adults with type 2 diabetes, which reflects patients that doctors see in their daily practice.7
Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/CARMELINA
* Primary endpoint defined as time to first occurrence of the 3-P MACE (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke)
† Key secondary endpoint defined as time to first occurrence of sustained end stage kidney disease (ESKD), death due to kidney disease, or a sustained decrease in eGFR from baseline of ≥40 percent compared to placebo
‡ Assessed by an independent clinical event committee in a blinded way
§ Glomerular filtration rate below 30 mL/min/m2
Phone: +49 (6132) 77 2012
Lilly Diabetes and Lilly USA
Gregory Andrew Kueterman
Director of Communications
Phone: +1 (317) 432-5195
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Moldova Citizenship-by-Investment Program Completes First Successful Application21.5.2019 12:07:00 EEST | Tiedote
As concessionaire of the Moldova Citizenship-by-Investment (MCBI) program, Henley & Partners is pleased to note the successful completion of the first citizenship-by-investment application in the country. Henley & Partners has over 20 years of experience in strategic consulting, working with sovereign states around the globe in the design, set-up, and operation of the world’s most respected investment migration programs. The completion of the first citizenship-by-investment application process in Moldova clearly illustrates the features that are at the core of the MCBI program: impressive efficiency and a firm commitment to best practice. Within a three-month window, applicants are thoroughly screened in a multi-stage due diligence process that ensures only highly credible international investors are granted Moldovan citizenship. There are currently over 30 applications in process, which is a testament to the international investment community’s growing appreciation of the value of the
comforte AG Launches New Payments Industry Data Security Solution21.5.2019 11:50:00 EEST | Tiedote
comforte AG today announced its Data Security Solution and Practice for the Payments Industry. The solution is making its debut at Card Forum 2019, the annual gathering of card and payment executives from the industry’s leading issuers, networks, retailers and innovators. Card Forum 2019 is being held this week in New Orleans. comforte AG has over a decade of history working with payment service providers (PSPs) to achieve compliance with data security regulations, in particular PCI DSS, as well as with more recent legislation such as the EU's General Data Protection Regulation (GDPR) or the upcoming California Consumer Privacy Act (CCPA). Our new solution will provide PSPs with enterprise-grade data security that not only fulfills key requirements of existing regulations, but will also help them to prepare for PSD2, which comes into effect in September of this year. PSD2 and open banking offer PSPs numerous opportunities to generate additional revenue, reduce costs, and increase marke
Lion/Gem Luxembourg 3 S.a.r.l. Announce Second Quarter Results for FY 201921.5.2019 11:00:00 EEST | Tiedote
The Second Quarter Results for FY19 (to 30 September 2019) for Lion/Gem Luxembourg 3 S.a.r.l. (associated with Young’s Seafood Limited) will be made available on our Investor Relations website on May 21, 2019. The Second Quarter Results for FY19 call for investors that accompanies this information is scheduled to take place at 13:00 BST on May 21, 2019. The Second Quarter covers the quarter to 30 March 2019; the financial year end for Lion/Gem Luxembourg 3 S.a.r.l. is September 30, 2019. For further information: If you are an investor or a potential investor in the 8¼%/ 9% Senior PIK Notes due 2019, of Lion/Gem Luxembourg 3 S.a.r.l., and would like access to this information, please register your interest on our Investor Relations website: https://youngsseafood.co.uk/investors/. If you have any questions about the registration process or need further information, please do not hesitate to contact Nicholas Donnelly, Communications Manager at Young’s Seafood: nicholas.donnelly@youngsseaf
Arthur D. Little: Nord Stream 2 Provides Economic Benefits, Generates Innovation and Helps to Develop Contractors’ Businesses21.5.2019 11:00:00 EEST | Tiedote
The second part of a recent report from Arthur D. Little (ADL) – “Nord Stream 2 economic impact in the construction phase” – analyzes the economic effects (job creation and GDP) of the ongoing project to build two new gas pipelines from Russia to Germany. The report, which is a follow-up to an earlier report created in 2017, analyzes the current status of project investment and concludes that the total economic benefit to the European Union (EU) represents €9.9 billion for building the pipelines. In comparison to the first report (2017), which was carried out in the procurement phase, more than twice as much CAPEX has now been committed and spent in several EU and non-EU countries now that the project is in the middle of construction. More than 1,000 contractors from all over Europe and Russia are contributing to the realization of the project. This includes both large international firms providing materials or construction services and small enterprises providing expert services. Furt
1 In 10 Banks Will Disappear over the Next 5 Years, According to A.T. Kearney21.5.2019 11:00:00 EEST | Tiedote
A ten-year study from global management consultancy A.T. Kearney has found that the profit of European retail banks/divisions is at an all-time high, driven by a positive economic environment and lower risks (risk costs relative to total income at lowest level 5% compared to 12% in 2008). Yet, the topline stagnates at (+ 1% in western Europe). A.T. Kearney’s ‘Retail Banking Radar 2019’ analyzes data from 92 banks across Europe and found that despite continued strong growth in volumes, income remains weak with a dramatic drop in income per client (-1.1% 2018 vs 2017; -11% 2018 vs 2008). Meanwhile, a quarter (24.6%) of bank branches across Europe has closed since 2008. The study shows that the industry faces a critical transformation amidst rising consumer demand for digital banking and the growing possibilities of open banking, revealing four key areas: Redefine target operating models, accelerate cost reduction and introduce new agile ways of working Rebalance the organization both in
EURid Q1 2019 Progress Report Now Available21.5.2019 11:00:00 EEST | Tiedote
Today EURid released its Q1 2019 Progress Report, sharing its quarterly statistics and developments. Highlights include: The quarter posted a renewal rate of 78.2%; The top country for growth for the quarter is Ireland, followed by Sweden and Portugal, which remains in the TOP 3 after leading in Q4 2018; The top ten countries with the most .eu registrations are Germany (984 311), the Netherlands (475 514), France (328 863), Poland (265 807), Italy (265 060), the United Kingdom (188 505), Czech Republic (157 804), Belgium (142 756), and Spain (120 189); Developments throughout the quarter also included: Further support to the Uganda Borehole project; The continuation of the Co-funded Marketing Programme for .eu accredited registrars until 2022, following an in-depth assessment by an external party and the introduction of several procedural refinements. View EURid’s Q1 2019 Progress Report About EURid EURid is the not-for-profit organisation that operates the .eu and .ею top-level domain
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme